bpc-157
Peptideexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2015 (NCT02637284)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)C[C@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)N[C@H](C(=O)O)C(C)C- Mol. weight
- 1419.56 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297358 ↗
Also known as
- bepecin
- bepecin
- bepecin
- booly protection compound 15
- bpc 15
- bpc-15
- bpc 157
- bpc-157
- bpc-157
- bpc-157
- l-valine, glycyl-l-alpha-glutamyl-l-prolyl-l-prolyl-l-prolylglycyl-l-lysyl-l-prolyl-l-alanyl-l-alpha-aspartyl-l-alpha-aspartyl-l-alanylglycyl-l-leucyl-
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02637284 | Phase 1 | Oct 1, 2015 | PharmaCotherapia d.o.o. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PharmaCotherapia d.o.o. | For profit | 1 | 1 | 1 | 2015 |
1 organizations
Page 1 / 1